Systemic Lupus Erythematosus | Access and Reimbursement | US | 2016
The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved for this indication in almost 60 years. Several biologics are in late-stage development for moderate to severe SLE, including agents targeting a previously underserved subpopulation of SLE patients, those with active lupus nephritis. Systemic Lupus Erythematosus ¦Access & Reimbursement ¦US examines the prescribing and reimbursement environment for Benlysta (IV) and emerging SLE agents in the United States, according to surveyed rheumatologists and managed care organization (MCO) pharmacy directors and medical directors. This content explores how physicians and payers perceive current and emerging SLE therapies and the reimbursement dynamics that will promote or restrict market access of these agents.
